Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.6%

2 terminated out of 56 trials

Success Rate

92.0%

+5.5% vs benchmark

Late-Stage Pipeline

21%

12 trials in Phase 3/4

Results Transparency

26%

6 of 23 completed with results

Key Signals

6 with results92% success

Data Visualizations

Phase Distribution

45Total
Not Applicable (28)
P 2 (5)
P 3 (1)
P 4 (11)

Trial Status

Completed23
Recruiting16
Not Yet Recruiting13
Terminated2
Withdrawn1
Enrolling By Invitation1

Trial Success Rate

92.0%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (56)

Showing 20 of 20 trials
NCT07740668Not ApplicableNot Yet Recruiting

Efficacy of Transcutaneous Electrical Stimulation Therapy in the Treatment of Overactive Bladder Developing After Stroke

NCT07736560CompletedPrimary

Effects of Antimuscarinic Drugs on Ejaculation Duration and Refractory Period in Men With Overactive Bladder

NCT07728747Not ApplicableCompletedPrimary

Bladder Training With or Without Biofeedback-Assisted Pelvic Floor Muscle Training for Women With Wet Overactive Bladder

NCT07711808Phase 4Not Yet RecruitingPrimary

Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study

NCT07707791Not ApplicableNot Yet RecruitingPrimary

Pretibial TENS for Pain and Anxiety During Intravesical OnabotulinumtoxinA Injection

NCT07195656Not ApplicableRecruitingPrimary

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07335484Not ApplicableRecruiting

Aquarius Pilot Study to Evaluate the New Axonics Trial System

NCT06789406Not ApplicableRecruiting

PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB

NCT07405554Phase 2RecruitingPrimary

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

NCT07206446Not ApplicableCompletedPrimary

A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

NCT07635251Not ApplicableNot Yet RecruitingPrimary

A Novel Wearable Transcutaneous Tibial Nerve Stimulation (TTNS) Device in the Treatment of Patients With Overactive Bladder (OAB) and Nocturia

NCT07635212Not ApplicableNot Yet RecruitingPrimary

Efficacy of Probiotics for OAB Patients With Anxiety

NCT07193407Not ApplicableRecruitingPrimary

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07545148Not Yet RecruitingPrimary

Real-world Experiences and Voices Exploring the Actual Lived Burden of OAB: A Mixed-methods Multi-country PROMs Study on OAB Patients' Quality of Life

NCT07300904Not ApplicableNot Yet RecruitingPrimary

Tensi+ for Treating Overactive Bladder

NCT07553065Phase 2Not Yet RecruitingPrimary

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT06944392Not ApplicableRecruitingPrimary

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

NCT07540273Not ApplicableNot Yet RecruitingPrimary

Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder

NCT07473310Phase 4RecruitingPrimary

Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women

NCT05702294Not ApplicableCompleted

Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries .

Scroll to load more

Research Network

Activity Timeline